Track topics on Twitter Track topics that are important to you
Hutchison China MediTech (Chi-Med) completed patient enrollment in a China Phase III trial of fruquintinib as a treatment for patients with non-small cell lung cancer. The trial, which enrolled 527 NSCLC patients who have failed two earlier treatments, will administer fruquintinib as a single agent. Chi-Med has started a Phase II trial in NSCLC as an adjunct to Iressa® (gefitinib) as a first-line treatment for lung cancer. The CFDA has already accepted an NDA for fruquintinib in colorectal cancer. More details....
Stock Symbol: (AIM/NSDQ: HCM)
Share this with colleagues:
Original Article: Chi-Med Enrolls 527 Lung Cancer Patients for China Trial of FruquintinibNEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...